This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Advocacy Perspective

Michael J. Fitzpatrick, MSW

Published: November 1, 2003

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Advocacy groups like the National Alliance for theMentally Ill (NAMI) have spent the last 25 years supporting research for a new generation of medications totreat major mental illness, recognizing that the old medications had significant problems with side effects and, insome cases, efficacy. About 10 years ago, new medications—atypical antipsychotics and new antidepressants—began to appear. There was great celebration within NAMIbecause, for the first time, scientific advances joined withother evidence-based treatments and services to create asystem where we could begin to achieve recovery frommental illness.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: